Why Influencers Use the FDA to Bash Research Peptides

The FDA's drug review budget is not funded by taxpayers. It is funded by the pharmaceutical companies whose drugs it reviews, and that single fact explains almost everything about how the system actually works.

The mechanism is something called PDUFA, the Prescription Drug User Fee Act, which is the law that allows pharmaceutical companies to pay fees directly to the FDA in exchange for having their drug applications reviewed. The FY2024 application fee is $4,198,000 per drug. One application. And because hundreds of applications move through the agency each year, those fees now make up approximately 65% of the FDA's entire human drug review budget. The agency responsible for deciding which drugs are safe and which are not is funded, in the majority, by the companies submitting the drugs.

That is not a conspiracy theory. That is the published federal budget.

The relationship does not end when drugs get approved. A 2018 investigation published in Science found that 62% of FDA medical officers who left the agency between 2006 and 2019 went directly to work for the pharmaceutical industry. The FDA commissioner who served from 2017 to 2019 left and joined Pfizer's board of directors the same year he stepped down. The people who spend years learning how the approval system works, who understand its exact requirements and pressure points, consistently move into roles where they are paid by the companies that benefited from their decisions. On top of that, the pharmaceutical and health products industry spent $374 million on federal lobbying in 2023 alone, which works out to roughly three lobbyists for every single member of Congress.

So the structure is: companies fund the agency that reviews them, former agency officials go work for those companies, and those same companies spend hundreds of millions per year ensuring that elected officials stay friendly to the arrangement.

Now understand why this matters for peptides specifically.

Bringing a drug through FDA approval costs a median of approximately $985 million in capitalized research and development costs, according to a 2020 analysis published in JAMA Internal Medicine. A company will spend close to a billion dollars on that process only if it can recoup the investment, which means it needs a patent. A patent means no competitor can sell the same molecule for a set period of time, which means the company can charge whatever it wants during that window and recover the cost.

Peptides are a problem for this model. Many research peptides are naturally occurring sequences, meaning they exist in biology already, and naturally occurring sequences cannot be patented. There is no proprietary claim to make. A company that spent $985 million pushing a naturally occurring peptide through FDA approval would immediately face generic competition with no legal barrier to stop it. The math never works. So no pharmaceutical company submits the application, the peptide never gets reviewed, and it permanently sits in a category called "unapproved," not because it is dangerous, but because the approval process was designed around a profit structure that excludes it by definition.

The FDA does not approve things that are safe. It approves things that are profitable enough to justify the fee and the development cost. Those are different standards.

This is the system that some influencers point to when they argue that research chemicals are unsafe because they lack FDA approval. The argument sounds reasonable on its surface because most people assume FDA approval is a scientific judgment about safety and efficacy. What it is, structurally, is a financial gatekeeping process that costs nearly a billion dollars to enter, is funded by the companies submitting drugs, and is staffed by officials who regularly move into those same companies afterward.

Compounded peptides occupy a specific and telling category within this. They are the same molecules, often manufactured to similar or identical specifications, but dispensed through a pharmacy under a physician's supervision rather than sold as an approved drug. The compounding pharmacy route exists inside the regulatory system. It has the appearance of institutional legitimacy. And some people selling compounded peptides use that appearance to position themselves as the responsible choice while arguing against research peptides sourced through other channels.

The distinction they are drawing is not scientific. It is commercial.

If someone is anti-government when the government's policies restrict their preferred lifestyle choices, and then turns around and uses FDA approval status as the authority that validates their business model, those two positions cannot coexist honestly. Either the FDA's approval process is a reliable measure of safety, in which case it should apply consistently, or it is a pay-to-play system built around pharmaceutical profit, in which case citing it as the reason to buy your product specifically is using the corruption you claim to oppose.

There is a version of this argument worth taking seriously, which is that quality control in research chemical supply chains is genuinely inconsistent, and that purity and dosing accuracy vary more than they would in a regulated manufacturing environment. That concern is real. But the answer to inconsistent manufacturing standards is better manufacturing standards, not deference to a regulatory body whose budget comes from the industry it regulates.

The FDA is not a neutral scientific institution that pharmaceutical companies occasionally influence around the edges. The funding structure, the revolving door employment pattern, and the lobbying expenditure all describe a system where the financial relationship between regulator and regulated is structural, not incidental. Pointing to that system as your safety credential is not consumer protection. It is borrowing the credibility of an institution whose credibility you would never defend if it weren't making you money.

---

References

1. FDA PDUFA Fee Schedule — Federal Register (published annually). FY 2024 application fee: $4,198,000.
2. FDA Budget Justification to Congress — PDUFA user fees fund approximately 65% of CDER/CBER human drug review budget.
3. Piller, C. (2018). "Is FDA's revolving door open too wide?" Science. Found 62% of FDA medical officers who left between 2006-2019 went to work for pharmaceutical industry.
4. OpenSecrets.org — Center for Responsive Politics. Pharmaceutical/health products industry spent $374 million on federal lobbying in 2023, #1 ranked industry. Approximately 1,500-1,800 registered lobbyists (roughly 3:1 ratio to members of Congress).
5. Scott Gottlieb served as FDA Commissioner 2017-2019, joined Pfizer board of directors in 2019.
6. Wouters, O.J., McKee, M., Luyten, J. (2020). "Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018." JAMA Internal Medicine. Median capitalized cost: $985 million per drug.

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness